Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorth EA, Rugo HS. Breast. In: Amin M, Edge SB, Greene FL, Compton CC, Gershenwald JE, Brookland RK, editors. AJCC Cancer Staging Man. 8th ed. Chicago, IL: Springer; 2016. p. 589–638.

Google Scholar 

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–75. https://doi.org/10.1093/jnci/dji172.

Article  PubMed  Google Scholar 

Abraham HG, Xia Y, Mukherjee B, Merajver SD. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Res Treat. 2021;185(1):229–38. https://doi.org/10.1007/s10549-020-05938-2.

Article  PubMed  Google Scholar 

Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9–23. https://doi.org/10.3233/bd-2006-22103.

Article  PubMed  PubMed Central  Google Scholar 

Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033–41. https://doi.org/10.1002/bjs.11469.

Article  CAS  PubMed  Google Scholar 

Laohavinij S, Ruikchuchit K, Maneechavakajorn J. Survival and prognostic factors of stage I-III breast cancer. J Med Assoc Thai. 2013;96(Suppl 3):S23-34.

PubMed  Google Scholar 

Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis. 2005;22:35–44. https://doi.org/10.3233/bd-2006-22105.

Article  PubMed  Google Scholar 

Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(2):235–43. https://doi.org/10.1007/s10549-021-06434-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postlewait LM, Tesihome M, Adesoye T, DeSnyder SM, Lim B, Kuerer H, et al. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Onc. 2021;28(13):8610–21. https://doi.org/10.1245/s10434-021-10148-1.

Article  Google Scholar 

Le-Petross H, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson E, Harrell R, et al. MRI Features of Inflammatory Breast Cancer. AJR Am J Roentgenol. 2011;197(4):W769-76. https://doi.org/10.2214/AJR.10.6157.

Article  PubMed  Google Scholar 

Droulias CA, Sewell CW, Mcsweeney MB, Powell RW. Inflammatory carcinoma of the breast: A correlation of clinical, radiologic and pathogic findings. Ann Surg. 1976;184(2):217–22. https://doi.org/10.1097/00000658-197608000-00014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 5.2024). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 2024 Oct 27.

Adesoye T, Everidge S, Chen J, Sun SX, Teshome M, Valero V, et al. Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy. Ann Surg Oncol. 2023;30:6232–40. https://doi.org/10.1245/s10434-023-13906-5.

Article  PubMed  Google Scholar 

Romanoff A, Zabor E, Petruolo O, Stempel M, El-Tamer M, Morrow M, et al. Does non-metastatic inflammatory breast cancer have a worse prognosis than other non-metastatic T4 cancers? Cancer. 2018;124(22):4314–21. https://doi.org/10.1002/cncr.31757.

Article  CAS  PubMed  Google Scholar 

van Uden DJP, van Maaren MC, Bult P, Strobbe LJA, van der Hoeven JJM, Blanken-Peeters CFJM, et al. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. Breast Cancer Res Treat. 2019;176(1):217–26. https://doi.org/10.1007/s10549-019-05219-7.

Article  PubMed  PubMed Central  Google Scholar 

Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program. Oncotarget. 2017;8(30):49370–9. https://doi.org/10.18632/oncotarget.17217.

Article  PubMed  PubMed Central  Google Scholar 

Chainitikun S, Rodrigo Espinosa Fernandez J, Long J, Iwase T, Kida K, Wang X, et al. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021;16(4):e0250057. https://doi.org/10.1371/journal.pone.0250057.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsai C, Li J, Gonzalez-Angulo A, Allen P, Woodward W, Ueno N, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of Neoadjuvant HER2-directed therapy. Am J Clin Oncol. 2015;38(3):242–7. https://doi.org/10.1097/COC.0b013e3182937921.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parrish KM, Thomas SM, Cartwright SB, van den Bruele AB, Zasloff R, DiLalla GA, et al. Rates of pathologic complete response and overall survival in patients with inflammatory breast cancer: a national cancer database study. Ann Surg Oncol. 2024;31(12):8057–67. https://doi.org/10.1245/s10434-024-16026-w.

Article  PubMed  Google Scholar 

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(3):515–23. https://doi.org/10.1093/annonc/mdq345.

Article  CAS  Google Scholar 

Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–26. https://doi.org/10.1056/NEJMoa2202809.

Article  CAS  PubMed  Google Scholar 

MD Anderson Cancer Center. Clinical treatment algorithms: Inflammatory breast cancer. www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/cancer-treatment/ca-%20treatment-breast-inflammatory-web-algorithm.pdf. Accessed 12 Nov 2024.

Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9. https://doi.org/10.1007/s002800050664.

Article  CAS  PubMed  Google Scholar 

Thoms W, McNeese M, Fletcher G, Buzdar A, Singletary SE, Oswald M. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):739–45. https://doi.org/10.1016/0360-3016(89)90060-6.

Article  PubMed  Google Scholar 

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15(6):640–7. https://doi.org/10.1016/S1470-2045(14)70080-4.

Article  CAS  PubMed  Google Scholar 

Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. https://doi.org/10.1016/S1470-2045(11)70336-9.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. https://doi.org/10.1056/NEJMoa1814017.

Article  Google Scholar 

Li J, Gonzalez-Angulo A, Allen P, Yu T, Woodward W, Ueno N, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011;16(12):1675–83. https://doi.org/10.1634/theoncologist.2011-0196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curcio LD, Rupp E, Williams WL, Chu DZ, Clarke K, Odom-Maryon T, et al. Beyond palliative mastectomy in inflammatory breast cancer–a reassessment of margin status. Ann Surg Oncol. 1999;6(3):249–54. https://doi.org/10.1007/s10434-999-0249-3.

Article  CAS  PubMed  Google Scholar 

Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, et al. Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery. Ann Surg Oncol. 2017;24(10):2981–8. https://doi.org/10.1245/s10434-017-5952-x.

Article  PubMed